EFFECT OF AMIODARONE IN PREVENTION OF ATRIAL FIBRILLATION IMMEDIATELY AFTER RELEASE OF AORTIC CROSS-CLAMP

Lingaraj Sahu; Alok Samantaray; Shashi Sankar Behera

doi:10.22159/ajpcr.2018.v11i3.23097

Authors

Lingaraj Sahu Department of Anaesthesiology, KIMS, Bhubaneswar,Odisa , India.
Alok Samantaray Department of Anaesthesiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Shashi Sankar Behera Department of Obstetrics and Gynaecology, KIMS, Bhubaneswar, Odisa

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i3.23097

Keywords:

Amiodarone, Atrial fibrillation, Aortic cross-clamp

Abstract

Â Objective: The objective of this study is to determine the efficacy of a bolus dose of amiodarone administered by the way of cardiopulmonary bypass pump before releasing of aortic cross-clamp (ACC) in the prevention of atrial fibrillation.

Methods: In this prospective study, 22 non-diabetic patients were randomly assigned in a double-blind fashion to either amiodarone or placebo group. In amiodarone group injection amiodarone 3 mg/kg in 10 ml normal saline (amiodarone group, Group A, n=10) and in control group (control group, Group P, n=12), the same volume of normal saline was administered 3 min before the release of ACC. Initial rhythm after the release of ACC was noted.

Results: The major rhythm after the release of ACC was ventricular arrhythmia in control group (n=5, 40%), whereas in amiodarone group, it is normal sinus rhythm (n=7, 63%). Only the need of cardioversion/defibrillation and the amount of energy needed was less in the amiodarone group but not reached statistical significance level. There was a trend toward a higher ventricular rate in control group compared to amiodarone group, but it never reached statistical significance level (114Â±46 vs. 97Â±29, p=0.3). One patient in amiodarone group required temporary pacemaker for sustained atrioventricular block with heart rate of <50 beats/min and continued on temporary pacemaker for 48 h.

Downloads

Download data is not yet available.

Author Biography

Lingaraj Sahu, Department of Anaesthesiology, KIMS, Bhubaneswar,Odisa , India.

asst professor,anaesthesia

References

Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.

Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982;306:1018-22.

Alpert JS, Petersen P, Godtfredsen J. Atrial fibrillation: Natural history, complications, and management. Annu Rev Med 1988;39:41-52.

Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation â€“ pharmacological intervention in atrial fibrillation (PIAF): A randomised trial. Lancet 2000;356:1789-94.

Vaturi M, Sagie A, Shapira Y, Feldman A, Fink N, Strasberg B, et al. Impact of atrial fibrillation on clinical status, atrial size and hemodynamics in patients after mitral valve replacement. J Heart Valve Dis 2001;10:763-6.

Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. N Engl J Med 2000;342:913-20.

Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN, et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.

Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE, et al. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998;81:995-8.

Chakraborty A, Mondal C, Sinha S, Mandal J, Chandra AK. Amiodarone induced oxidative stress in stress - Vulnerable organs of adult male rats. Asian J Pharm Clin Res 2014;7:177-83.

Installe E, Schoevaerdts JC, Gadisseux P, Charles S, Tremouroux J. Intravenous amiodarone in the treatment of various arrhythmias following cardiac operations. J Thorac Cardiovasc Surg 1981;81:302-8.

Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 1970;39:657-67.

Vaughan William EM. A classification of antiarrhythmic agents reassessed after a decade of new drugs. J Clinpharmacol 1984; 24:129.

Connolly SJ. Evidence based analysisof amiodarone efficacy and safety. N Engl J Med 1990;322:863-8.

Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29.

Rady MY, Ryan T, Starr NJ. Preopeative therapy with amiodarone and the incidance of acute organ dysfunction after cardiac surgery. Anesth Analg 1997;337:1785.

Carlson MD. How to manage atrial fibrillation: An update on recent clinical trials. Cardiol Rev 2001;9:60-9.

Brodsky MA, Allen BJ, Walker CJ 3rd, Casey TP, Luckett CR, Henry WL, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572-5.

Selvaraj T, Kiran U, Das S, Chauhan S, Sahu B, Gharde P, et al. Effect of single intraoperative dose of amiodarone in patients with rheumatic valvular heart disease and atrial fibrillation undergoing valve replacement surgery. Ann Card Anaesth 2009;12:10-6.